drugset / Trial / NCT04297436
Gonococcal Vaccine Study in Key Populations in Kenya
Completed
50 enrolled
University of Oxford
KEMRI-Wellcome Trust Collaborative Research Program · collab
NaSingle-groupOpen-labelBasic science
Summary
Gonorrhoea is a sexually transmitted infection that can infect both men and women. It can cause infections in the genitals, rectum, and throat. It is a very common infection, especially among young people aged 18-25 years. Meningococcal disease and gonorrhoea are caused by bacteria that are closely related but cause different diseases that are spread in different ways. New evidence suggests that the Meningococcal B vaccine (Bexsero®) licensed outside of Kenya against meningococcal B disease may also be effective against gonorrhoea due to genetic similarities between the two organisms causing the two diseases. The aim of this study is to generate data to develop a gonorrhoea vaccine, using an existing vaccine against meningococcal disease
Timeline
- Start
- 2021-05-31
- Primary completion
- 2022-02-05
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexsero | Vaccine | — | — |